Their product is designed to improve clinical outcomes for patients with superficial transitional cell carcinoma of the bladder by reducing disease recurrence and avoiding cystectomy in advanced stages. The treatment combines hyperthermia and chemotherapy, and has been clinically tested and well tolerated. Synergo's focus is on developing minimally invasive therapies that benefit both patients and healthcare systems. Their technology involves radiofrequency induced thermo-chemotherapy for the treatment of invasive cancer. Headquartered in Amstelveen, The Netherlands, Synergo aims to provide effective and repeatable treatments for bladder cancer.